Prometheus Biosciences Inc 's ROA from the third quarter of 2023 to the third quarter of 2022 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Prometheus Biosciences Inc 's ROA in the third quarter of 2023?
Prometheus Biosciences Inc recorded a cumulative net loss of $-151 million during 12 months ending in the third quarter of 2023, resulting in a negative return on assets (ROA) of -29.59%.

However, within the Healthcare sector 485 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2023 quarter, so far to 4290, from total ROA ranking in the fourth quarter of 2022 at 5155.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2023) III. Quarter	(Dec 31 2022) IV. Quarter	(Sep 30 2022) III. Quarter	(Jun 30 2022) II. Quarter	(Mar 31 2022) I. Quarter
Y / Y Total Assets Change	199.08 %	176.61 %	3.29 %	-24.13 %	-20.76 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-151	-142	-133	-123	-108
Return On Assets (TTM)	-29.59 %	-37.05 %	-50.28 %	-46.94 %	-38.56 %
RXDX's Total Ranking	# 4290	# 5155	# 4872	# 4980	# 4791
Total Assets (TTM) in million	758	741	298	238	254
Seq. Total Assets Change	2.38 %	148.22 %	25.61 %	-6.31 %	-5.31 %
Seq. Net Income Change	-	-	-	-	-

RXDX's 5 Years Annual ROA >> Back to RXDX Management Effectiveness >> Compare RXDX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 192
Sector	# 486
Overall	# 4197

Return On Assets Statistics
High	Average	Low
-29.59 %	-50.39 %	-83.78 %
(Mar 31 2023)		(Sep 30 2017)

Financial Statements
Prometheus Biosciences Inc 's Assets	$ 758 million	RXDX's Balance sheet
Prometheus Biosciences Inc 's Income	$ -41 million	Quarterly RXDX's Income Statement
RXDX's Income by Division		See RXDX's Income by Division

Annual Return On Assets	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2016) FY 2016	(Dec 31 2015) FY 2015	(Dec 31 2014) FY 2014
Y / Y Total Assets Change	176.61 %	-50.62 %	176.47 %	129.94 %	59.99 %
Total Assets in million	741	268	542	196	85
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-142	-90	-104	-92	-40
Annual Return On Assets	-19.14 %	-33.68 %	-19.11 %	-47.14 %	-46.88 %

RXDX's 5 Years Annual ROA >> Back to RXDX Management Effectiveness >> Compare RXDX ROA to its Competitors

More Return On Assets Ratios
RXDX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RXDX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RXDX's Competitors
Subscribers only: Roa for Prometheus Biosciences Inc 's Suppliers
Subscribers only: Return On Assets for RXDX's Customers

You may also want to know
RXDX's Roi	RXDX's Inventory Turnover Ratio	RXDX's Growth Rates	RXDX's Dividend Comparisons
	RXDX's Profitability Ratios	RXDX's Asset Turnover Ratio	RXDX's Dividend Growth
RXDX's Roe	RXDX's Valuation Ratios	RXDX's Financial Strength Ratios	RXDX's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2023, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:39:22+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.